{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:26:07Z","timestamp":1793633167019,"version":"4.5.1"},"reference-count":31,"publisher":"Society of Nuclear Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,8,7]]},"published-print":{"date-parts":[[2026,11]]},"DOI":"10.2967\/jnumed.126.272854","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:10:25Z","timestamp":1789063825000},"page":"1764-1770","source":"Crossref","is-referenced-by-count":0,"title":["Targeted RPT of CEACAM5-Expressing Human Xenografts Using an Albumin-Binding Domain\u2013Fused C9 Affibody: Proof-of-Principle Study"],"prefix":"10.2967","volume":"67","author":[{"given":"Ruonan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Papalanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Oroujeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Bezverkhniaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Konijnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Orlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-\u00c5ke","family":"Nygren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torbj\u00f6rn","family":"Gr\u00e4slund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Tolmachev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"2026110206250913000_67.11.1764.1","doi-asserted-by":"crossref","first-page":"100986","DOI":"10.1016\/j.medj.2025.100986","article-title":"Advances and perspectives in CEA-targeted therapies: from classic biomarker toward actionable therapeutic target","volume":"7","author":"Sun","year":"2026","journal-title":"Med"},{"key":"2026110206250913000_67.11.1764.2","first-page":"5929s","article-title":"Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial","volume":"55","author":"Wong","year":"1995","journal-title":"Cancer Res"},{"key":"2026110206250913000_67.11.1764.3","first-page":"5935s","article-title":"Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies","volume":"55","author":"Sharkey","year":"1995","journal-title":"Cancer Res"},{"key":"2026110206250913000_67.11.1764.4","first-page":"10","article-title":"Phase I study of yttrium-90 radiolabeled M5A anti-carcinoembryonic antigen humanized antibody in patients with advanced carcinoembryonic antigen producing malignancies","volume":"35","author":"Akhavan","year":"2020","journal-title":"Cancer Biother Radiopharm"},{"key":"2026110206250913000_67.11.1764.5","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.3.1.53"},{"key":"2026110206250913000_67.11.1764.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-2998(99)80028-2"},{"key":"2026110206250913000_67.11.1764.7","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s00259-020-04989-3","article-title":"Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study","volume":"48","author":"Touchefeu","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026110206250913000_67.11.1764.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.252791"},{"key":"2026110206250913000_67.11.1764.9","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/cncr.30390","article-title":"Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: safety, feasibility, and long-term efficacy results of a prospective phase 2 study","volume":"123","author":"Sahlmann","year":"2017","journal-title":"Cancer"},{"key":"2026110206250913000_67.11.1764.10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/978-1-61779-974-7_38","article-title":"Radiolabeled antibodies for cancer imaging and therapy","volume":"907","author":"Barbet","year":"2012","journal-title":"Methods Mol Biol"},{"key":"2026110206250913000_67.11.1764.11","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.376"},{"key":"2026110206250913000_67.11.1764.12","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41571-025-01069-z","article-title":"The molecular blueprint of targeted radionuclide therapy","volume":"22","author":"Primac","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"2026110206250913000_67.11.1764.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2017.04.007"},{"key":"2026110206250913000_67.11.1764.14","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3390\/cancers12030651","article-title":"Affibody molecules as targeting vectors for PET imaging","volume":"12","author":"Tolmachev","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026110206250913000_67.11.1764.15","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3390\/biomedicines12051088","article-title":"Imaging of HER2-expressing cancers as a key to guide HER2-targeted therapy","volume":"12","author":"Eissler","year":"2024","journal-title":"Biomedicines"},{"key":"2026110206250913000_67.11.1764.16","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1007\/s00259-024-06840-5","article-title":"Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile","volume":"51","author":"Liu","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026110206250913000_67.11.1764.17","unstructured":"A first-in-human phase 1 safety and biodistribution of [177Lu]Lu-ABY-271 in subjects with HER2-positive metastatic breast cancer. ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/study\/NCT07081555. Accessed August 24, 2026."},{"key":"2026110206250913000_67.11.1764.18","doi-asserted-by":"crossref","first-page":"102512","DOI":"10.1016\/j.tranon.2025.102512","article-title":"An anti-CEA affibody showing high-definition staining in human pancreatic cancer tissue sections and selective tumor targeting in\u00a0vivo","volume":"61","author":"Nilvebrant","year":"2025","journal-title":"Transl Oncol"},{"key":"2026110206250913000_67.11.1764.19","doi-asserted-by":"crossref","first-page":"151442","DOI":"10.1016\/j.ijbiomac.2026.151442","article-title":"Tumour accumulation of anti-carcinoembryonic antigen affibody-albumin-binding domain fusion depends on domains\u2019 order","volume":"355","author":"Papalanis","year":"2026","journal-title":"Int J Biol Macromol"},{"key":"2026110206250913000_67.11.1764.20","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/sj.bjc.6601362","article-title":"Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer","volume":"89","author":"Azria","year":"2003","journal-title":"Br J Cancer"},{"key":"2026110206250913000_67.11.1764.21","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2006.320"},{"key":"2026110206250913000_67.11.1764.22","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1021\/acs.molpharmaceut.8b00393","article-title":"S. Evaluation of the therapeutic potential of a HER3-binding Affibody construct TAM-HER3 in comparison with a monoclonal antibody, seribantumab","volume":"15","author":"Orlova","year":"2018","journal-title":"Mol Pharm"},{"key":"2026110206250913000_67.11.1764.23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/14736691211060117","article-title":"ICRU report 96:dosimetry-guided radiopharmaceutical therapy","volume":"21","author":"Sgouros","year":"2021","journal-title":"J ICRU"},{"key":"2026110206250913000_67.11.1764.24","first-page":"149","article-title":"Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes","volume":"41","author":"Stabin","year":"2000","journal-title":"J Nucl Med"},{"key":"2026110206250913000_67.11.1764.25","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzh056"},{"key":"2026110206250913000_67.11.1764.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264126"},{"key":"2026110206250913000_67.11.1764.27","unstructured":"Actinium 225 labeled anti-CEA antibody (Ac225-DOTA-M5A) for the treatment of CEA producing advanced or metastatic cancers. ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/study\/NCT05204147. Accessed August 24, 2026."},{"key":"2026110206250913000_67.11.1764.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2007.10.010"},{"key":"2026110206250913000_67.11.1764.29","doi-asserted-by":"publisher","DOI":"10.1039\/C3CS60304K"},{"key":"2026110206250913000_67.11.1764.30","doi-asserted-by":"publisher","DOI":"10.1186\/2191-219X-1-24"},{"key":"2026110206250913000_67.11.1764.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2013.07.015"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.126.272854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T14:26:08Z","timestamp":1793629568000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.126.272854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11,2]]},"published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.2967\/jnumed.126.272854"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.126.272854","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}